Last updated on April 2018

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients


Brief description of study

The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.

Detailed Study Description

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral formulation is the focus of current development efforts. Rucaparib is currently being investigated as monotherapy in patients with cancer associated with breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutations.

While PARP inhibitors have demonstrated consistent robust clinical activity in patients with relapsed ovarian cancer associated with HRD, prospective studies evaluating efficacy and safety of PARPi versus standard of care chemotherapy have been limited. The primary purpose of this Phase 3 study is to compare the efficacy and safety of rucaparib versus chemotherapy as treatment for relapsed ovarian cancer in patients with a deleterious BRCA1/2 mutation in their tumor.

Clinical Study Identifier: NCT02855944

Contact Investigators or Research Sites near you

Start Over

Clovis Oncology Clinical Trial Information

The University of Arizona Cancer Center
Tucson, AZ United States
  Connect »

Krishnansu Tewari, MD

University of California Irvine Health Chao Family Comprehensive Cancer Center
Long Beach, CA United States
  Connect »

Clovis Oncology Clinical Trial Information

Pacific Cancer Care
Monterey, CA United States
  Connect »

Ling Ma, MD

Rocky Mountain Cancer Center
Denver, CO United States
  Connect »

Clovis Oncology Clinical Trial Information

Florida Hospital Cancer Institute
Orlando, FL United States
  Connect »

Sharad Ghamande, MD

Augusta University
Augusta, GA United States
  Connect »

Christopher Darus, MD

Maine Medical Center/Maine Medical Partners Women's Health
Scarborough, ME United States
  Connect »

Shelly Seward, MD

Karmanos Cancer Institute/Wayne State University
Detroit, MI United States
  Connect »

Clovis Oncology Clinical Trial Information

Women's Contemporary Care Associates (WCCA) - Mineola
Mineola, NY United States
  Connect »

Thomas Herzog, MD

University of Cincinnati
Cincinnati, OH United States
  Connect »

Clovis Oncology Clinical Trial Information

Debreceni Egyetem Klinikai K zpont
Debrecen, Hungary
  Connect »

Clovis Oncology Clinical Trial Information

Nizhny Novgorod, Russian Federation
  Connect »

Clovis Oncology Clinical Trial Information

Saint Petersburg, Russian Federation
  Connect »

Clovis Oncology Clinical Trial Information

Saint-Petersburg, Russian Federation
  Connect »

Clovis Oncology Clinical Trial Information

Newcastle upon Tyne, United Kingdom
  Connect »

Lee-May Chen, M.D.

University of California San Francisco
San Francisco, CA United States
  Connect »

Sonia Robazetti

The University of Texas Health Science Center at Houston
Houston, TX United States
  Connect »

Clovis Oncology Clinical Trial Information

Seattle Cancer Care Alliance
Seattle, WA United States
  Connect »